In the United States (US), biotechnology research platform provider TeselaGen Biotechnology, Inc. has announced that it is extending its relationship with the Joint BioEnergy Institute (JBEI) through 2027 via a new multi-year contract.
Please reload the page
Do you want to read the whole article?
- Six editions per year
- Full access to all digital content
- The E-magazine Bioenergy international
- And more ...
TeselaGen and the Joint BioEnergy Institute (JBEI) have signed a new 5-year contract to add expanded workflow capabilities, extending their relationship through 2027.
JBEI, led by Lawrence Berkeley National Laboratory (Berkeley Lab) in California (CA), is one of four US Department of Energy (DOE) Bioenergy Research Centers (BRC) that conduct innovative research on biofuels and bioproducts.
TeselaGen and JBEI have been collaborating since 2017 on informatics tools for synthetic biology workflows. Over that time, JBEI has continued to deliver novel scientific advancements and breakthroughs needed to produce renewable, carbon-neutral biofuels from non-food plant fiber.
Biomanufacturing has become a vital component of the US strategy, which has been recently ratified by the US National Biotechnology and Biomanufacturing Initiative, to provide a Sustainable, Safe, and Secure American Bioeconomy. We are honored to continue to work with JBEI with their on-going efforts to enable the cost-effective biological production of fuels, products, and other components that are traditionally made through chemical processes, said Dr Eduardo Abeliuk, CEO and Co-founder of TeselaGen.
TeselaGen’s biotech R&D software platform allows biologists, lab technicians, and bioinformaticians to run scalable experiments, seamlessly connecting data, tools, and protocols for high-throughput workflows, allowing them to collaboratively design, build, test, and continually learn.
A modern approach coupled with AI modeling, opens the door for radical transformation of biology and biochemistry and enables rapid expansion of potential applications across biological R&D, agritech, protein engineering, antibody optimization, gene & cell therapy, and more.